Ignite Creation Date:
2025-12-26 @ 11:10 AM
Ignite Modification Date:
2025-12-29 @ 8:37 AM
Study NCT ID:
NCT00778128
Status:
COMPLETED
Last Update Posted:
2010-09-06
First Post:
2008-10-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}], 'ancestors': [{'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C538828', 'term': 'CP 4126'}, {'id': 'D000093542', 'term': 'Gemcitabine'}], 'ancestors': [{'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 26}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2010-09', 'completionDateStruct': {'date': '2010-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2010-09-03', 'studyFirstSubmitDate': '2008-10-22', 'studyFirstSubmitQcDate': '2008-10-22', 'lastUpdatePostDateStruct': {'date': '2010-09-06', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-10-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Step 1: MTD of oral CP-4126 in patients with advanced solid tumours, followed by establishing the recommended dose', 'timeFrame': '6 months'}, {'measure': 'Step 2: Pharmacokinetic parameters comparison of oral CP-4126 with IV gemcitabine', 'timeFrame': '12 months'}], 'secondaryOutcomes': [{'measure': 'Tolerability of oral CP-4126', 'timeFrame': '12 months'}, {'measure': 'Biovailability of oral CP-4126', 'timeFrame': '12 months'}, {'measure': 'Preliminary assessment of antitumor activity of oral CP-4126', 'timeFrame': '18 months'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['CP-4126', 'Cancer', 'Metastatic', 'Solid tumours', 'Gemzitabine', 'Gemzar'], 'conditions': ['Solid Tumors']}, 'referencesModule': {'references': [{'pmid': '23345000', 'type': 'DERIVED', 'citation': 'Stuurman FE, Voest EE, Awada A, Witteveen PO, Bergeland T, Hals PA, Rasch W, Schellens JH, Hendlisz A. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors. Invest New Drugs. 2013 Aug;31(4):959-66. doi: 10.1007/s10637-013-9925-z. Epub 2013 Jan 24.'}]}, 'descriptionModule': {'briefSummary': 'At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will be randomized. They will receive at days 1 and 8 in a double cross design either oral CP-4126 at the recommended dose or gemcitabine 1000mg/m2 intravenously. At both steps, the schedule of treatment will be day 1, 8, 15 q4w until complete response or disease worsening/ progressing. All further treatment at step 2 will be oral CP-4126.', 'detailedDescription': 'This is a multicentre clinical study conducted in Belgium and in The Netherlands. The study is a phase I divided in 2 steps: The first step is a dose escalation to define the RD. At the second step the PK profile of oral CP-4126 will be compared with the PK profile of IV gemcitabine. In addition, the study is conducted to characterize the tolerability of oral CP-4126, to evaluate its bioavailability, and to make a preliminary assessment of antitumor activity in patients with solid tumours.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Histologically or cytologically confirmed solid tumour diagnosis\n2. Locally advanced or metastatic disease, for which there is no known effective treatment\n3. Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status\n4. Age 18 years or more\n5. Life expectancy \\> 3 months\n6. Adequate hematological and biological functions:\n7. Signed informed consent\n\nExclusion Criteria:\n\n1. Symptomatic brain metastases\n2. Current peripheral neuropathy of grade \\> 1 according to the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0\n3. Radiotherapy\n\n * to more than 30 % of bone marrow\n * single dose up to 8 Gy\n * less than one week prior to the study treatment\n * of the upper GI tract\n4. Mucositis of the upper digestive tract, including stomatitis\n5. Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study\n6. Previous anticancer therapy (chemotherapy, hormone therapy or immunotherapy) within 30 days prior to the first dose of oral CP-4126 \\[6 weeks for mitomycin C and BCNU (= carmustine) and CCNU (=lomustine)\\]\n7. Requirement of concomitant treatment with a non-permitted medication including alternative drugs and high doses of vitamins\n8. History of allergic reactions to gemcitabine\n9. Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection)\n10. Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance\n11. Pregnant or breast feeding women\n12. Absence of adequate contraception for both male and female fertile patients for the duration of the study; and also for six months after last treatment\n13. Known positive status for HIV and/or hepatitis B or C\n14. Any reason why, in the investigator's opinion, the patient should not participate\n15. Condition that impairs ability to swallow pills\n16. Coeliac disease or any other lipid malabsorption syndrome\n17. Drug and/or alcohol abuse"}, 'identificationModule': {'nctId': 'NCT00778128', 'briefTitle': 'A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour', 'organization': {'class': 'INDUSTRY', 'fullName': 'Clavis Pharma'}, 'officialTitle': 'A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour', 'orgStudyIdInfo': {'id': 'CP4126-111'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '1', 'description': 'Step 1: Dose escalation - oral CP-4126\n\nStep 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8.', 'interventionNames': ['Drug: CP-4126', 'Drug: Gemcitabine']}, {'type': 'EXPERIMENTAL', 'label': '2', 'description': 'Step 1: Dose escalation - oral CP-4126\n\nStep 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1.', 'interventionNames': ['Drug: CP-4126', 'Drug: Gemcitabine']}], 'interventions': [{'name': 'CP-4126', 'type': 'DRUG', 'description': 'Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression', 'armGroupLabels': ['1', '2']}, {'name': 'Gemcitabine', 'type': 'DRUG', 'description': 'Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression', 'armGroupLabels': ['1', '2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '1000', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Institute Jules Bordet', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'city': 'Amsterdam', 'country': 'Netherlands', 'facility': 'The Netherlands Cancer Institute', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}, {'city': 'Utrecht', 'country': 'Netherlands', 'facility': 'University Medical Centre Utrecht', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}], 'overallOfficials': [{'name': 'Ahmad H Awada, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Institute Jules Bordet'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Clavis Pharma', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Trygve Bergeland', 'oldOrganization': 'Clavis Pharma ASA'}}}}